356 related articles for article (PubMed ID: 16034525)
21. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
[TBL] [Abstract][Full Text] [Related]
22. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
23. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Khalil MA; Qiao W; Carlson P; George B; Javle M; Overman M; Varadhachary G; Wolff RA; Abbruzzese JL; Fogelman DR
Invest New Drugs; 2013 Oct; 31(5):1375-83. PubMed ID: 23645398
[TBL] [Abstract][Full Text] [Related]
24. [Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
Xu G; Wu K; Wang XP; Zhao S
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):986-91. PubMed ID: 16060994
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.
Bang S; Jeon TJ; Kim MH; Park JY; Park SW; Chung JB; Song SY
Pancreatology; 2006; 6(6):635-41. PubMed ID: 17159377
[TBL] [Abstract][Full Text] [Related]
26. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer.
Brodowicz T; Wolfram RM; Köstler WJ; Tomek S; Vaclavik I; Steger GG; Teleky B; Függer R; Jakesz R; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):623-8. PubMed ID: 11081453
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
Wang X; Ni Q; Jin M; Li Z; Wu Y; Zhao Y; Feng F
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):404-7. PubMed ID: 12408777
[TBL] [Abstract][Full Text] [Related]
29. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Kim H; Park JH; Shin SJ; Kim MJ; Bang SJ; Park NH; Nah YW; Nam CW; Joo KR; Min YJ
Chemotherapy; 2008; 54(1):54-62. PubMed ID: 18073472
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.
Chao Y; Wu CY; Wang JP; Lee RC; Lee WP; Li CP
Cancer Chemother Pharmacol; 2013 Sep; 72(3):637-42. PubMed ID: 23912692
[TBL] [Abstract][Full Text] [Related]
32. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Astsaturov IA; Meropol NJ; Alpaugh RK; Burtness BA; Cheng JD; McLaughlin S; Rogatko A; Xu Z; Watson JC; Weiner LM; Cohen SJ
Am J Clin Oncol; 2011 Feb; 34(1):70-5. PubMed ID: 20458210
[TBL] [Abstract][Full Text] [Related]
33. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E
J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
[TBL] [Abstract][Full Text] [Related]
37. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
39. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Kindler HL; Aklilu M; Nattam S; Vokes EE
Am J Clin Oncol; 2008 Dec; 31(6):553-6. PubMed ID: 19060586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]